Maynard Um
-
-
-
-
-
-
-
GRI Bio's (GRI) GRI-0621 Demonstrates Encouraging Safety Results at Planned Interim 6-Week Analysis in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis
-
-
-
-
-
-
-
GRI Bio, Inc (GRI) Reports Encouraging Interim 2-Week Safety Results from Ongoing Phase 2a Study of GRI-0621
-
-
-
-
-
-
-
GRI Bio, Inc (GRI) Raises a Total of $13.9M in Gross Proceeds Since the Beginning of 2024
-
-
-
-
-
-
-
GRI Bio, Inc (GRI) Announces Korea Patent Granted for Proprietary Natural Killer T Cell Modulators
-
-
-
404,878 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

